Videos

“[BPH treatment] has to be individualized to the motivations of the patient, and also what I call his "phenotype.” How big is his prostate? How bad is this problem? And what is his tolerance for side effects?” says Kevin T. McVary, MD.

Dr. McVary discusses individualizing care in men with BPH

“More research needs to be done, but I think this is something that gets the conversation started,” says Tony Chen, MD.

Patients with ED exhibit varying treatment patterns across races

“Patients want to see an improvement. They want a drug that obviously is efficacious and safe, where the side effects are low,” says David Staskin, MD.

Dr. Staskin discusses counseling patients on vibegron for OAB

“What was very impressive from the study was by sequentially using Cxbladder Triage, Detect, and Resolve, we could not only segregate those who had cancer versus not, but also those who had low-risk tumors versus high-risk tumors,” says Jay Raman, MD, FACS.

Noninvasive biomarker tests diagnose urothelial cancer in patients with hematuria 

“I think the real driving factor in all of this is that collecting smoking status and tobacco use is hard. It's difficult to get this information out. It requires a lot of time; it requires energy; it requires infrastructure in the data and the electronic medical record,” says Richard Matulewicz, MD, MS.

Dr. Matulewicz discusses underreported smoking status in GU cancer trials

“The reason that [long-term follow up is] important is because if you look at the best of hands, the incidence of recurrence of upper tract urothelial carcinoma, even for low and intermediate risk, is still very high,” says Karim Chamie, MD.

Dr. Chamie on durability of UGN-101 in low-grade UTUC

“My patient selection process for BPH treatments can be a little bit cumbersome and take time, but that's really because for the first time ever, we have so many different options available to men,” says Dean Elterman, MD, MSc, FRCSC.

Dr. Elterman weighs in on the growing number of BPH treatments available

“The purpose of [Cxbladder] Resolve is to identify not only those patients who are at higher risk for urothelial or urinary tract cancer, but those that have a high probability of an aggressive cancer, such as high-grade TA, carcinoma in situ, or T1 to T3,” says Jay Raman, MD, FACS.

Cxbladder tests identify high-impact and low-impact tumors

“The most important takeaway is really good preoperative counseling. Patients should not expect surgeries to be pain free,” says Sarah F. Faris, MD.

Dr. Faris on patient counseling in regards to postoperative opioid usage

“I think Aquablation is safe. It’s efficacious, especially in these large prostates,” says Kevin Zorn, MD, FRCSC, FACS.

UTv Videos